Aliases & Classifications for Spinocerebellar Degeneration

MalaCards integrated aliases for Spinocerebellar Degeneration:

Name: Spinocerebellar Degeneration 54 37 73
Spinocerebellar Tract Degeneration 73
Spinocerebellar Degenerations 55
Ataxia, Spinocerebellar 73

External Ids:

KEGG 37 H01616

Summaries for Spinocerebellar Degeneration

NINDS : 54 Ataxia often occurs when parts of the nervous system that control movement are damaged. People with ataxia experience a failure of muscle control in their arms and legs, resulting in a lack of balance and coordination or a disturbance of gait. While the term ataxia is primarily used to describe this set of symptoms, it is sometimes also used to refer to a family of disorders. It is not, however, a specific diagnosis. Most disorders that result in ataxia cause cells in the part of the brain called the cerebellum to degenerate, or atrophy. Sometimes the spine is also affected. The phrases cerebellar degeneration and spinocerebellar degeneration are used to describe changes that have taken place in a person’s nervous system; neither term constitutes a specific diagnosis. Cerebellar and spinocerebellar degeneration have many different causes. The age of onset of the resulting ataxia varies depending on the underlying cause of the degeneration. Many ataxias are hereditary and are classified by chromosomal location and pattern of inheritance: autosomal dominant,in which the affected person inherits a normal gene from one parent and a faulty gene from the other parent; andautosomal recessive, in which both parents pass on a copy of the faulty gene. Among the more common inherited ataxias are Friedreich’s ataxia and Machado-Joseph disease. Sporadic ataxias can also occur in families with no prior history. Ataxia can also be acquired. Conditions that can cause acquired ataxia include stroke, multiple sclerosis, tumors, alcoholism, peripheral neuropathy, metabolic disorders, and vitamin deficiencies.

MalaCards based summary : Spinocerebellar Degeneration, also known as spinocerebellar tract degeneration, is related to spinocerebellar ataxia 2 and dentatorubral-pallidoluysian atrophy, and has symptoms including ataxia, cerebellar ataxia and myoclonus. An important gene associated with Spinocerebellar Degeneration is ATXN1 (Ataxin 1), and among its related pathways/superpathways is Chks in Checkpoint Regulation. The drugs Clonidine and Estradiol valerate have been mentioned in the context of this disorder. Affiliated tissues include brain, cerebellum and liver, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Spinocerebellar Degeneration

Diseases related to Spinocerebellar Degeneration via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 66)
# Related Disease Score Top Affiliating Genes
1 spinocerebellar ataxia 2 31.5 ATXN2 ATXN3
2 dentatorubral-pallidoluysian atrophy 30.5 ATXN2 ATXN3
3 autosomal dominant cerebellar ataxia 29.4 ATXN1 ATXN2 ATXN3 TDP1
4 spinocerebellar ataxia 1 29.1 ATXN1 ATXN3
5 multiple system atrophy 1 29.0 ATXN1 GLUD1
6 machado-joseph disease 28.6 ATXN1 ATXN2 ATXN3
7 friedreich ataxia 1 28.6 ATXN1 ATXN2 ATXN3
8 aceruloplasminemia 28.5 ATXN1 ATXN2 ATXN3
9 hereditary ataxia 27.2 ATXN1 ATXN2 ATXN3 TDP1
10 spinocerebellar degeneration and corneal dystrophy 12.3
11 ataxias and cerebellar or spinocerebellar degeneration 12.2
12 spinocerebellar degeneration with macular corneal dystrophy, congenital cataracts, and myopia 11.9
13 primary cerebellar degeneration 11.1
14 spinocerebellar atrophy 11.0
15 mousa al din al nassar syndrome 10.9
16 spinocerebellar ataxia, x-linked 3 10.9
17 sensory ataxic neuropathy, dysarthria, and ophthalmoparesis 10.9
18 behr syndrome 10.9
19 gamma-glutamylcysteine synthetase deficiency, hemolytic anemia due to 10.9
20 laurence-moon syndrome 10.9
21 vitamin e, familial isolated deficiency of 10.9
22 neuronitis 10.3
23 adrenoleukodystrophy 10.1
24 motor neuron disease 10.0
25 neuropathy 10.0
26 cerebritis 10.0
27 langerhans cell histiocytosis 9.9
28 histiocytosis 9.9
29 neuronal intranuclear inclusion disease 9.9 ATXN1 ATXN3
30 spinal and bulbar muscular atrophy, x-linked 1 9.8 ATXN1 ATXN3
31 hereditary sensory neuropathy 9.8
32 hypertrophic neuropathy of dejerine-sottas 9.8
33 asthma 9.8
34 blind loop syndrome 9.8
35 supranuclear palsy, progressive, 1 9.8
36 tooth disease 9.8
37 hypoglycemia 9.8
38 amenorrhea 9.8
39 brainstem auditory evoked responses 9.8
40 roussy-levy hereditary areflexic dystasia 9.8
41 facial hemiatrophy 9.8
42 fatty liver disease, nonalcoholic 1 9.8
43 sensory peripheral neuropathy 9.8
44 encephalopathy 9.8
45 celiac disease 1 9.8
46 pyruvate dehydrogenase e1-beta deficiency 9.8
47 corneal dystrophy 9.8
48 myoclonus 9.8
49 ataxia-oculomotor apraxia 3 9.8
50 paraneoplastic syndromes 9.8

Comorbidity relations with Spinocerebellar Degeneration via Phenotypic Disease Network (PDN):


Acute Cystitis Cerebral Degeneration

Graphical network of the top 20 diseases related to Spinocerebellar Degeneration:



Diseases related to Spinocerebellar Degeneration

Symptoms & Phenotypes for Spinocerebellar Degeneration

UMLS symptoms related to Spinocerebellar Degeneration:


ataxia, cerebellar ataxia, myoclonus

GenomeRNAi Phenotypes related to Spinocerebellar Degeneration according to GeneCards Suite gene sharing:

26 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.53 ATXN3
2 Increased shRNA abundance (Z-score > 2) GR00366-A-13 9.53 ATXN3
3 Increased shRNA abundance (Z-score > 2) GR00366-A-143 9.53 ATXN3
4 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.53 ATXN3
5 Increased shRNA abundance (Z-score > 2) GR00366-A-195 9.53 ATXN3
6 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.53 GLUD1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-24 9.53 ATXN3
8 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.53 ATXN3 GLUD1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-54 9.53 ATXN3 GLUD1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.53 GLUD1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.53 ATXN3 GLUD1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.53 GLUD1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.53 ATXN3

MGI Mouse Phenotypes related to Spinocerebellar Degeneration:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.02 ATXN1 ATXN2 ATXN3 GLUD1 TDP1

Drugs & Therapeutics for Spinocerebellar Degeneration

Drugs for Spinocerebellar Degeneration (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 182)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clonidine Approved Phase 4 4205-90-7 2803
2 Estradiol valerate Approved, Investigational, Vet_approved Phase 4 979-32-8
3
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
4
Polyestradiol phosphate Approved Phase 4 28014-46-2
5
Pioglitazone Approved, Investigational Phase 4,Phase 3 111025-46-8 4829
6
Metformin Approved Phase 4 657-24-9 14219 4091
7
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
8
Citalopram Approved Phase 4 59729-33-8 2771
9
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
10
Amantadine Approved Phase 4 768-94-5 2130
11 insulin Phase 4
12 Analgesics Phase 4,Phase 1,Phase 2
13 Adrenergic Agents Phase 4
14 Adrenergic Agonists Phase 4
15 Adrenergic alpha-2 Receptor Agonists Phase 4
16 Adrenergic alpha-Agonists Phase 4
17 Mitogens Phase 4
18 Contraceptive Agents Phase 4
19 Sympatholytics Phase 4
20 Neurotransmitter Agents Phase 4,Phase 2,Phase 3
21 Hormone Antagonists Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable
22 Hormones Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable
23 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable
24 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
25 Estradiol 17 beta-cypionate Phase 4
26 Estradiol 3-benzoate Phase 4
27 Estrogens Phase 4
28 Antihypertensive Agents Phase 4,Phase 2
29 Insulin, Globin Zinc Phase 4
30 Autonomic Agents Phase 4,Phase 3,Early Phase 1,Not Applicable
31 Cholinergic Agents Phase 4,Phase 2,Phase 3
32 Muscarinic Antagonists Phase 4
33 Cholinergic Antagonists Phase 4
34 Serotonin Agents Phase 4
35 Serotonin Uptake Inhibitors Phase 4
36 Analgesics, Non-Narcotic Phase 4,Phase 1,Phase 2
37 Neurotransmitter Uptake Inhibitors Phase 4
38 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
39 Cytochrome P-450 Enzyme Inhibitors Phase 4
40 Parasympatholytics Phase 4
41 Dopamine Agents Phase 4
42 Dopamine Uptake Inhibitors Phase 4
43 Hypoglycemic Agents Phase 4,Phase 3
44 Antidepressive Agents Phase 4,Phase 2,Phase 3,Phase 1
45 Antidepressive Agents, Second-Generation Phase 4
46 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Not Applicable
47 Antiparkinson Agents Phase 4
48 Psychotropic Drugs Phase 4,Phase 2,Phase 3,Phase 1
49 Antiviral Agents Phase 4,Phase 3,Phase 2,Not Applicable
50 arginine Nutraceutical Phase 4

Interventional clinical trials:

(show top 50) (show all 123)
# Name Status NCT ID Phase Drugs
1 Status of Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis and Growth Failure in Ataxia Telangiectasia (AT) Unknown status NCT01052623 Phase 4 Somatropin, Clonidine, L-Arginin-Hydrochloride, Estradiol valerate
2 An Objective Double-blind Evaluation of Bupropion and Citalopram in an Individual With Friedreich Ataxia Completed NCT01716221 Phase 4 bupropion & Citalopram;Bupropion & Placebo;Placebo & Citalopram;Placebo & Placebo
3 Response of Individuals With Ataxia-Telangiectasia to Metformin and Pioglitazone Completed NCT02733679 Phase 4 Metformin;Pioglitazone
4 Amantadine for Improving Neurologic Symptoms in Ataxia-Telangiectasia Completed NCT00950196 Phase 4 amantadine sulphate
5 A Long-Term Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT01970124 Phase 3 KPS-0373, High dose;KPS-0373, Low dose
6 A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT01970137 Phase 3 KPS-0373, High dose;KPS-0373, Low dose
7 An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT01970111 Phase 3 KPS-0373, High dose;KPS-0373, Low dose
8 A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT01970098 Phase 3 KPS-0373, High dose;KPS-0373, Low dose;Placebo
9 Safety and Efficacy of Lithium Carbonate in Patients With Spinocerebellar Ataxia Type 3 Completed NCT01096082 Phase 2, Phase 3 Lithium Carbonate;Placebo
10 Efficacy of Riluzole in Hereditary Cerebellar Ataxia Completed NCT01104649 Phase 2, Phase 3 riluzole;Placebo comparator
11 Long-Term Safety Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia Completed NCT02797080 Phase 3 interferon γ-1b
12 Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study Completed NCT02593773 Phase 3 Interferon γ-1b
13 Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Completed NCT02415127 Phase 3 Interferon γ-1b;Placebo
14 Patient Reported Outcomes in Friedreich's Ataxia Patients After Withdrawal From Treatment With Idebenone (PROTI) Completed NCT01303406 Phase 3 Idebenone;Placebo
15 Long-Term Safety and Tolerability of Idebenone in Friedreich's Ataxia Patients (MICONOS Extension) Completed NCT00993967 Phase 3 idebenone
16 A Study of Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia (FRDA) Patients Completed NCT00905268 Phase 3 idebenone;Placebo
17 Effect of Pioglitazone Administered to Patients With Friedreich's Ataxia: Proof of Concept Completed NCT00811681 Phase 3 pioglitazone;Placebo
18 Study to Assess the Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients Completed NCT00697073 Phase 3 Idebenone
19 Study to Assess the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Completed NCT00537680 Phase 3 Idebenone;Idebenone;Placebo
20 Conjugate Pneumococcal Vaccine in Ataxia Telangiectasia (AT) Completed NCT00656409 Phase 3 Conjugated pneumococcal vaccine (Prevenar)
21 EDS in Ataxia Telangiectasia Patients Recruiting NCT02770807 Phase 3 EDS-EP dose range of ~5-10 mg DSP/infusion;EDS-EP dose range of ~14-22 mg DSP/infusion;Placebo
22 An Additional Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Active, not recruiting NCT02889302 Phase 3 KPS-0373;Placebo
23 Trial in Adult Subjects With Spinocerebellar Ataxia Active, not recruiting NCT02960893 Phase 2, Phase 3 BHV-4157;Placebo Comparator
24 An Open Pilot Trial of BHV-4157 Active, not recruiting NCT03408080 Phase 3 BHV-4157
25 Clinical Trial With Riluzole in Spinocerebellar Ataxia Type 2 (ATRIL) Not yet recruiting NCT03347344 Phase 3 Riluzole;Placebo
26 Open-label, Long-term, Extension Treatment Using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients With Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study Not yet recruiting NCT03563053 Phase 3
27 Pilot Study of Varenicline (Chantix®) in the Treatment of Friedreich's Ataxia Terminated NCT00803868 Phase 2, Phase 3 varenicline;placebo
28 A New Method to Treat Hereditary Cerebellar Ataxia - Umbilical Cord Mesenchymal Stem Cells Transplantation Unknown status NCT01489267 Phase 2
29 Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Hereditary Ataxia Unknown status NCT01360164 Phase 1, Phase 2
30 A Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT01004016 Phase 2 KPS-0373;Placebo
31 Phase II Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT00863538 Phase 2 KPS-0373
32 Study to Determine the Safety and Tolerability of Varenicline (Chantix®) in Treating Spinocerebellar Ataxia Type 3 Completed NCT00992771 Phase 2 varenicline;placebo
33 Safety and Efficacy of Intravenous Immune Globulin in Treating Spinocerebellar Ataxia Completed NCT01350440 Phase 2
34 Safety and Tolerability of Lithium in Spinocerebellar Ataxia 2 (SCA2) Completed NCT00998634 Phase 2 LITHIUM CARBONATE
35 A Phase II Double Blind Comparative Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT01384435 Phase 2 KPS-0373;KPS-0373;KPS-0373;KPS-0373;Placebo
36 High-Dose Intravenous Immunoglobulin to Treat Cerebellar Degeneration Completed NCT00034242 Phase 2 high-dose intravenous immunoglobulin (IVIG)
37 Study To Assess Safety, Tolerability and Efficacy of Intravenous Cabaletta in Patients With Machado-Joseph Disease Completed NCT02147886 Phase 2 Cabaletta for IV infusion once weekly during 24 weeks;Cabaletta for IV infusion once weekly during 24 weeks
38 The Influence of Deep TMS on Cerebellar Signs in Patients With Machado Joseph Disease Completed NCT02039206 Phase 2
39 Effect of Riluzole as a Symptomatic Approach in Patients With Chronic Cerebellar Ataxia Completed NCT00202397 Phase 2 Riluzole
40 A First in Human Study of RT001 in Patients With Friedreich's Ataxia Completed NCT02445794 Phase 1, Phase 2 RT001;RT001 comparator
41 A Phase IIa Trial to Test Safety and Efficacy Interferon Gamma Treatment in Elevating Frataxin Levels in FRDA Patients Completed NCT02035020 Phase 2 gamma interferon
42 Interferon Gamma-1b in Friedreich Ataxia (FRDA) Completed NCT01965327 Phase 2 Interferon Gamma-1b
43 EPI-743 in Friedreich's Ataxia Point Mutations Completed NCT01962363 Phase 2 EPI-743
44 Safety and Efficacy of EPI-743 in Patients With Friedreich's Ataxia Completed NCT01728064 Phase 2 Placebo;EPI-743 400 mg;EPI-743 200 mg
45 Efficacy Study of Epoetin Alfa in Friedreich Ataxia Completed NCT01493973 Phase 2 Epoetin alfa;Placebo
46 A Study of Resveratrol as Treatment for Friedreich Ataxia Completed NCT01339884 Phase 1, Phase 2 Resveratrol
47 Safety and Efficacy Study of A0001 in Subjects With Friedreich's Ataxia Completed NCT01035671 Phase 2 alpha-tocopherolquinone (A0001);alpha-tocopherolquinone (A0001);placebo
48 Safety Study of Carbamylated Erythropoietin to Treat Patients With the Neurodegenerative Disorder Friedreich's Ataxia Completed NCT01016366 Phase 2 Lu AA24493;Placebo
49 A Study Investigating the Long-term Safety and Efficacy of Deferiprone in Patients With Friedreich's Ataxia Completed NCT00897221 Phase 2 Deferiprone oral solution 100mg/mL;Deferiprone oral solution 100 mg/mL
50 Efficacy of EGb761 in Patients Suffering From Friedreich Ataxia Completed NCT00824512 Phase 2 EGb 761 120 mg;Placebo

Search NIH Clinical Center for Spinocerebellar Degeneration

Genetic Tests for Spinocerebellar Degeneration

Anatomical Context for Spinocerebellar Degeneration

MalaCards organs/tissues related to Spinocerebellar Degeneration:

41
Brain, Cerebellum, Liver, Eye, Testes, Spinal Cord, Cortex

Publications for Spinocerebellar Degeneration

Articles related to Spinocerebellar Degeneration:

(show top 50) (show all 153)
# Title Authors Year
1
Evaluation of walking smoothness using wearable robotic system curaraAr for spinocerebellar degeneration patients. ( 28814031 )
2017
2
Determination of the time course of caloric nystagmus in patients with spinocerebellar degeneration using caloric step stimulus procedure. ( 28949274 )
2017
3
Neuronal vacuolation and spinocerebellar degeneration associated with altered neurotransmission. ( 28677370 )
2017
4
Intrathecal baclofen pump in spinocerebellar degeneration. ( 27841225 )
2016
5
MRI-based cerebellar volume measurements correlate with the International Cooperative Ataxia Rating Scale score in patients with spinocerebellar degeneration or multiple system atrophy. ( 27536377 )
2016
6
A Homozygous RAB3GAP1:c.743delC Mutation in Rottweilers with Neuronal Vacuolation and Spinocerebellar Degeneration. ( 26968732 )
2016
7
"Cerebellar peduncle quarter notes" formed by the superior and middle cerebellar peduncles: comparison with a diffusion tensor study of spinocerebellar degeneration. ( 25749832 )
2015
8
Spinocerebellar degeneration: Discrepancies between clinical and pathological diagnoses. ( 26556659 )
2015
9
Quantitative analysis of upper-limb ataxia in patients with spinocerebellar degeneration. ( 24781836 )
2014
10
Hashimoto's encephalopathy as a treatable adult-onset cerebellar ataxia mimicking spinocerebellar degeneration. ( 23128836 )
2013
11
Progressive cerebellar atrophy: hereditary ataxias and disorders with spinocerebellar degeneration. ( 23622410 )
2013
12
Acoustic characteristics of ataxic speech in Japanese patients with spinocerebellar degeneration (SCD). ( 22268904 )
2012
13
Spinocerebellar degenerations. ( 21496573 )
2011
14
[An autopsied case of progressive supranuclear palsy, initially diagnosed as spinocerebellar degeneration with severe olivopontocerebellar involvement]. ( 22019867 )
2011
15
Anesthetic management of a patient with spinocerebellar degeneration. ( 21772692 )
2011
16
Secondary amenorrhea in a woman with spinocerebellar degeneration treated with thyrotropin-releasing hormone: a case report and in vitro analysis. ( 22152284 )
2011
17
Difference in the effects of tandospirone on ataxia in various types of spinocerebellar degeneration: an open-label study. ( 20809107 )
2010
18
Evaluation of the effect of thyrotropin releasing hormone (TRH) on regional cerebral blood flow in spinocerebellar degeneration using 3DSRT. ( 19286195 )
2009
19
Cognitive impairment in spinocerebellar degeneration. ( 19295212 )
2009
20
Tract-by-tract morphometric and diffusivity analyses in vivo of spinocerebellar degeneration. ( 19021844 )
2009
21
Analysis of subjective evaluations of the functions of tele-coaching intervention in patients with spinocerebellar degeneration. ( 18525137 )
2008
22
Effect of coaching on psychological adjustment in patients with spinocerebellar degeneration: a pilot study. ( 17984151 )
2007
23
Catatonic stupor superimposed on hereditary spinocerebellar degeneration resolved with electroconvulsive therapy. ( 16764981 )
2006
24
Adrenoleukodystrophy manifesting as spinocerebellar degeneration. ( 16804268 )
2006
25
Longitudinal study of bone and calcium metabolism and fracture incidence in spinocerebellar degeneration. ( 17035703 )
2006
26
Peripheral nerve pathology in two rottweilers with neuronal vacuolation and spinocerebellar degeneration. ( 16301586 )
2005
27
Thalamic stimulation for disabling tremor in a patient with spinocerebellar degeneration. ( 16155369 )
2005
28
Influence of repetitive transcranial magnetic stimulation on disease severity and oxidative stress markers in the cerebrospinal fluid of patients with spinocerebellar degeneration. ( 15845214 )
2005
29
[Clinical features and molecular genetics of autosomal recessive spinocerebellar degenerations]. ( 15651291 )
2004
30
Spinocerebellar degeneration with negative electroretinogram: dysfunction of the bipolar cells. ( 15573948 )
2004
31
Mice lacking phosphatidylinositol transfer protein-alpha exhibit spinocerebellar degeneration, intestinal and hepatic steatosis, and hypoglycemia. ( 12788952 )
2003
32
[A quantitative evaluation of spinocerebellar degeneration by an acoustic analysis--the effect of taltirelin hydrate on patients with Machado-Joseph disease]. ( 12884823 )
2003
33
Nystagmus-sensation dissociation in spinocerebellar degeneration. ( 14606594 )
2003
34
D-cycloserine for the treatment of ataxia in spinocerebellar degeneration. ( 12736088 )
2003
35
Spinocerebellar degeneration. ( 14521474 )
2003
36
Double-blind crossover study of branched-chain amino acid therapy in patients with spinocerebellar degeneration. ( 11897246 )
2002
37
Ambulatory blood pressure monitoring in patients with spinocerebellar degeneration. ( 12225317 )
2002
38
Transcranial magnetic stimulation alleviates truncal ataxia in spinocerebellar degeneration. ( 11784843 )
2002
39
Reduced pre-movement facilitation of motor evoked potentials in spinocerebellar degeneration. ( 11440743 )
2001
40
Vestibular evoked myogenic potentials in patients with spinocerebellar degeneration. ( 11132714 )
2000
41
Diffusion- and T2-weighted MRI of the transverse pontine fibres in spinocerebellar degeneration. ( 11151684 )
2000
42
Clinical and genetic aspects of spinocerebellar degeneration. ( 10970057 )
2000
43
Therapeutic efficacy of transcranial magnetic stimulation for hereditary spinocerebellar degeneration. ( 10674722 )
1999
44
Autosomal dominant spinocerebellar degenerations. Clinical, pathological, and genetic correlations. ( 10367323 )
1999
45
Chronic vitamin E deficiency causing spinocerebellar degeneration, peripheral neuropathy, and centro-cecal scotomata. ( 10198917 )
1999
46
Branched-chain amino acid therapy for spinocerebellar degeneration: a pilot clinical crossover trial. ( 10397076 )
1999
47
Parvocellular and magnocellular visual processing in spinocerebellar degeneration and Parkinson's disease: an event-related potential study. ( 10402092 )
1999
48
Molecular genetic diagnosis of Friedreich's ataxia in a pedigree with apparent autosomal dominant spinocerebellar degeneration. ( 9886474 )
1999
49
A novel point mutation in X-linked adrenoleukodystrophy presenting as a spinocerebellar degeneration. ( 10319888 )
1999
50
Late-onset progressive spinocerebellar degeneration in Brittany Spaniel dogs. ( 9678519 )
1998

Variations for Spinocerebellar Degeneration

Expression for Spinocerebellar Degeneration

Search GEO for disease gene expression data for Spinocerebellar Degeneration.

Pathways for Spinocerebellar Degeneration

Pathways related to Spinocerebellar Degeneration according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.41 ATXN1 ATXN2 ATXN3

GO Terms for Spinocerebellar Degeneration

Cellular components related to Spinocerebellar Degeneration according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nuclear matrix GO:0016363 8.96 ATXN1 ATXN3
2 nuclear inclusion body GO:0042405 8.62 ATXN1 ATXN3

Molecular functions related to Spinocerebellar Degeneration according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein C-terminus binding GO:0008022 8.62 ATXN1 ATXN2

Sources for Spinocerebellar Degeneration

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....